Navigation Links
CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
Date:3/3/2008

VIENNA, Va., March 3 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM) provided details today at its 2008 Annual Meeting of Shareholders on groundbreaking activities currently underway at its manufacturing facility near Baltimore, Maryland. The facility will be used to manufacture Multikine(R), the Company's lead compound, for a pivotal Phase III clinical trial as first-line therapy of previously untreated head and neck cancer patients. The facility, which is being built by the design builder BE&K (http://www.bek.com/index.asp), is expected to be completed during the third quarter of 2008, with manufacturing and patient enrollment to begin soon thereafter.

"I am excited to announce to our shareholders the excellent progress we have made in constructing our manufacturing facility in the short period of time since we have broken ground," said Geert Kersten, CEL-SCI's Chief Executive Officer. "We believe the facility will provide us with tight control over the manufacturing process, eliminating a key risk of the pivotal trial. Multikine represents a completely novel medicine with blockbuster potential to treat a large unmet medical need and we are eager to begin this open label trial."

Mr. Kersten continued, "We are starting to receive more recognition for our work. The February 2008 issue of MedAdNews, a highly respected and authoritative publication serving the pharmaceutical industry, ran its 8th annual report on FUTURE BLOCKBUSTERS stating that 'These medicines are expected to eventually garner FDA approval and break the annual billion-dollar sales barrier'. Our Multikine was one of the 10 medicines named."

The article can be accessed on CEL-SCI's website at http://www.cel-sci.com under recent media coverage.

At the Annual Shareholder's Meeting, the Company's executives also provided highlights from fiscal year 2007. Some of the highlights include:

-- FDA clearance of Multikine for Phase III clinical trial in head and

neck cancer

-- Raised U.S. $15 million

-- Multikine granted Orphan drug designation in U.S.

-- Started build-out of manufacturing facility for Multikine to support

upcoming Phase III study and future commercial sale

-- Started planning and pricing of global clinical trial designed to lead

to marketing approval for Multikine

All matters submitted to a vote of the shareholders were approved by a vote of the shareholders at the Annual Meeting.

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2007. The Company undertakes no obligation to publicly release the result of any revision to these forward- looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CEL-SCI Corporation Releases Letter to Shareholders
2. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
3. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
4. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
5. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
6. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
7. Dialysis Corporation of America Announces Fiscal Year 2007 Earnings Release Date
8. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
9. National Atlantic Holdings Corporation to Report Fourth Quarter and Year-End 2007 Earnings on March 17, 2008
10. Linkwell Corporations Skin Disinfectant Product Chosen for 2008 Beijing Olympic Games
11. Partners Center for Connected Health and EMC Corporation Launch New Web-Based Remote Monitoring Program to Help Employees Fight Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 23, 2017 , ... Natural Subsistence, a company known for ... and nutrition, announced its product Leyzene is now available for purchase on Go4ItNutrition.com, ... that help people improve all aspects of their health so they can live ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... non-steroidal skincare products, was awarded as winners of American Dreams & Good Housekeeping ... was hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to host Shriners ... events will be located in the Main West Entrance of The Boulevard (in front ... No appointment is necessary and each child with a parent or guardian will be ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power of ... a wife, mother and grandmother committed to sharing her many spiritual adventures which affirm ... book presents actual events in the life of her family, which validate her deep ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 ... Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria ... of the Primary Hyperoxaluria (Genito Urinary System And ... a rare condition characterized by recurrent kidney and ... a substance called oxalate. Symptoms include blood in ...
(Date:3/23/2017)... Wash. , March 23, 2017   ... contract management in the cloud, today announced ... and Budgeting solution designed to improve clinical trials ... Management (ICM) platform , the solution speeds up ... with contract research organizations (CRO). ...
(Date:3/23/2017)... Research and Markets has announced the addition ... their offering. ... The global capillary electrophoresis market to grow at a CAGR of ... Capillary Electrophoresis Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: